TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

Core Insights - TG Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, with a fireside chat scheduled for June 4, 2025, at 12:50 PM ET [1] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis (RMS) [3] - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS who have active disease [3]